176 related articles for article (PubMed ID: 26732684)
21. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
22. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
[TBL] [Abstract][Full Text] [Related]
23. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
24. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.
Gollub EL; Vaughan R
AIDS Educ Prev; 2022 Aug; 34(4):311-324. PubMed ID: 35994576
[TBL] [Abstract][Full Text] [Related]
25. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
[TBL] [Abstract][Full Text] [Related]
27. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
van der Straten A; Panther L; Laborde N; Hoesley CJ; Cheng H; Husnik MJ; Horn S; Nel A; Soto-Torres L; Chen BA
AIDS Behav; 2016 Nov; 20(11):2644-2653. PubMed ID: 26837628
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
[TBL] [Abstract][Full Text] [Related]
29. Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.
Akil A; Parniak MA; Dezzuitti CS; Moncla BJ; Cost MR; Li M; Rohan LC
Drug Deliv Transl Res; 2011 Jun; 1(3):209-222. PubMed ID: 22708075
[TBL] [Abstract][Full Text] [Related]
30. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides.
Fetherston SM; Malcolm RK; Woolfson AD
Ther Deliv; 2010 Dec; 1(6):785-802. PubMed ID: 22834014
[TBL] [Abstract][Full Text] [Related]
31. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
[TBL] [Abstract][Full Text] [Related]
32. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
33. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1.
Gupta KM; Pearce SM; Poursaid AE; Aliyar HA; Tresco PA; Mitchnik MA; Kiser PF
J Pharm Sci; 2008 Oct; 97(10):4228-39. PubMed ID: 18338805
[TBL] [Abstract][Full Text] [Related]
34. Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring.
Balkus JE; Brown ER; Palanee-Phillips T; Matovu Kiweewa F; Mgodi N; Naidoo L; Mbilizi Y; Jeenarain N; Gaffoor Z; Siva S; Nair G; Pather A; Baeten JM
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):e8-e10. PubMed ID: 28961677
[No Abstract] [Full Text] [Related]
35. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
37. Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions.
Murphy DJ; McCoy CF; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
Int J Pharm; 2019 Jun; 565():351-357. PubMed ID: 31085254
[TBL] [Abstract][Full Text] [Related]
38. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
39. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
[TBL] [Abstract][Full Text] [Related]
40. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
